Centessa Pharmaceuticals plc (CNTA)
CNTA Stock Price Chart
Explore Centessa Pharmaceuticals plc interactive price chart. Choose custom timeframes to analyze CNTA price movements and trends.
CNTA Company Profile
Discover essential business fundamentals and corporate details for Centessa Pharmaceuticals plc (CNTA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 May 2021
Employees
77.00
Website
https://www.centessa.comCEO
Saurabh Saha
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
CNTA Financial Timeline
Browse a chronological timeline of Centessa Pharmaceuticals plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.39.
Earnings released on 12 Aug 2025
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%.
Earnings released on 14 May 2025
EPS came in at -$0.20 surpassing the estimated -$0.35 by +42.86%, while revenue for the quarter reached $15.00M , beating expectations by +600.00%.
Earnings released on 24 Mar 2025
EPS came in at -$0.34 surpassing the estimated -$0.38 by +10.53%, while revenue for the quarter reached $952.25K .
Earnings released on 12 Nov 2024
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%.
Earnings released on 13 Aug 2024
EPS came in at -$0.40 falling short of the estimated -$0.38 by -5.26%.
Earnings released on 13 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.41 by +7.32%.
Earnings released on 28 Mar 2024
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%, while revenue for the quarter reached $6.91M .
Earnings released on 13 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.46 by +13.04%.
Earnings released on 14 Aug 2023
EPS came in at -$0.26 surpassing the estimated -$0.43 by +39.53%.
Earnings released on 12 May 2023
EPS came in at -$0.53 falling short of the estimated -$0.41 by -29.27%.
Earnings released on 30 Mar 2023
EPS came in at -$0.45 surpassing the estimated -$0.48 by +6.25%.
Earnings released on 10 Nov 2022
EPS came in at -$0.57 falling short of the estimated -$0.49 by -16.33%.
Earnings released on 10 Aug 2022
EPS came in at -$0.69 falling short of the estimated -$0.56 by -23.21%.
Earnings released on 16 May 2022
EPS came in at -$0.60 surpassing the estimated -$0.70 by +14.29%.
Earnings released on 30 Mar 2022
EPS came in at -$0.68 falling short of the estimated -$0.60 by -13.33%.
Earnings released on 15 Nov 2021
EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%.
Earnings released on 16 Aug 2021
EPS came in at -$0.65 surpassing the estimated -$0.73 by +10.96%.
Earnings released on 1 Jun 2021
EPS came in at -$2.75 .
Earnings released on 31 Dec 2020
EPS came in at -$0.03 .
Earnings released on 30 Sept 2020
EPS came in at -$0.02 .
CNTA Stock Performance
Access detailed CNTA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.